1.Persistent SARS-CoV-2 Infection in a Patient Who Developed COVID-19 While Receiving Rituximab: A Case Report
Toshiaki MOTEGI ; Shigen HAYASHI ; Kenta NAKAMURA ; Kenya KURAMOTO ; Tatsuya AKIYAMA ; Hiroshi EBE ; Hirofumi SAKURAI ; Akihiro NOMURA
Journal of the Japanese Association of Rural Medicine 2025;74(4):397-402
This case involves a man in his 60s who was undergoing rituximab therapy and developed COVID-19 pneumonia and showed persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite treatments with dexamethasone, remdesivir, tocilizumab, and other drugs, the patient remained SARS-CoV-2 positive and ultimately died of respiratory failure. Patients receiving B-cell depletion therapy have an increased risk of persistent viral infections due to immunosuppression, underscoring the importance of early intervention with antiviral drugs and neutralizing antibodies in such cases.
Result Analysis
Print
Save
E-mail